Going Viral with Cancer Immunotherapy

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2014 Jul 4

PMID 24990523

Citations 336

Authors

Brian D Lichty

Caroline J Breitbach

David F Stojdl

John C Bell

Affiliations

Soon will be listed here.

Abstract

Recent clinical data have emphatically shown the capacity of our immune systems to eradicate even advanced cancers. Although oncolytic viruses (OVs) were originally designed to function as tumour-lysing therapeutics, they have now been clinically shown to initiate systemic antitumour immune responses. Cell signalling pathways that are activated and promote the growth of tumour cells also favour the growth and replication of viruses within the cancer. The ability to engineer OVs that express immune-stimulating 'cargo', the induction of immunogenic tumour cell death by OVs and the selective targeting of OVs to tumour beds suggests that they are the ideal reagents to enhance antitumour immune responses. Coupling of OV therapy with tumour antigen vaccination, immune checkpoint inhibitors and adoptive cell therapy seems to be ready to converge towards a new generation of multimodal therapeutics to improve outcomes for cancer patients.

Citing Articles

VSV drives CD8 T cell-mediated tumour regression through infection of both cancer and non-cancer cells.

Rajwani J, Vishnevskiy D, Turk M, Naumenko V, Gafuik C, Kim D Nat Commun. 2024; 15(1):9933.

PMID: 39548070 PMC: 11567966. DOI: 10.1038/s41467-024-54111-6.

Characterisation and Sensitivity of a Canine Mast Cell Tumour Line to Oncolytic Viruses.

Mehrani Y, Kakish J, Napoleoni C, Thompson J, Knapp J, Minott J Vet Comp Oncol. 2024; 23(1):42-51.

PMID: 39526468 PMC: 11830461. DOI: 10.1111/vco.13024.

Enhanced Oncolytic Potential of Engineered Newcastle Disease Virus Lasota Strain through Modification of Its F Protein Cleavage Site.

Li Z, Qian W, Zhang Y, Liao C, Chen J, Ding K Microorganisms. 2024; 12(10).

PMID: 39458338 PMC: 11510066. DOI: 10.3390/microorganisms12102029.

Oncolytic Viruses as Reliable Adjuvants in CAR-T Cell Therapy for Solid Tumors.

Stilpeanu R, Secara B, Cretu-Stancu M, Bucur O Int J Mol Sci. 2024; 25(20).

PMID: 39456909 PMC: 11508774. DOI: 10.3390/ijms252011127.

Improved antitumor effectiveness of oncolytic HSV-1 viruses engineered with IL-15/IL-15Rα complex combined with oncolytic HSV-1-aPD1 targets colon cancer.

Hu Z, Li Y, Yang J, Liu J, Zhou H, Sun C Sci Rep. 2024; 14(1):23671.

PMID: 39389985 PMC: 11467195. DOI: 10.1038/s41598-024-72888-w.

References

Elzey B, Siemens D, Ratliff T, Lubaroff D . Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int J Cancer. 2001; 94(6):842-9. DOI: 10.1002/ijc.1556. View

Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C . Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009; 15(10):1170-8. DOI: 10.1038/nm.2028. View

Pol J, Zhang L, Bridle B, Stephenson K, Resseguier J, Hanson S . Maraba virus as a potent oncolytic vaccine vector. Mol Ther. 2013; 22(2):420-429. PMC: 3916044. DOI: 10.1038/mt.2013.249. View

Huang B, Sikorski R, Kirn D, Thorne S . Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1. Gene Ther. 2010; 18(2):164-72. DOI: 10.1038/gt.2010.121. View

Li H, Peng K, Dingli D, Kratzke R, Russell S . Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther. 2010; 17(8):550-8. PMC: 2907639. DOI: 10.1038/cgt.2010.10. View

Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila P, Ugolini M . Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res. 2010; 70(11):4297-309. DOI: 10.1158/0008-5472.CAN-09-3567. View

Garber K . China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 2006; 98(5):298-300. DOI: 10.1093/jnci/djj111. View

Leveille S, Goulet M, Lichty B, Hiscott J . Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation. J Virol. 2011; 85(23):12160-9. PMC: 3209377. DOI: 10.1128/JVI.05703-11. View

Liu B, Robinson M, Han Z, Branston R, English C, Reay P . ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003; 10(4):292-303. DOI: 10.1038/sj.gt.3301885. View

10.

Russell S, Peng K, Bell J . Oncolytic virotherapy. Nat Biotechnol. 2012; 30(7):658-70. PMC: 3888062. DOI: 10.1038/nbt.2287. View

11.

Vigil A, Park M, Martinez O, Chua M, Xiao S, Cros J . Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res. 2007; 67(17):8285-92. DOI: 10.1158/0008-5472.CAN-07-1025. View

12.

Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A . Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A. 2012; 109(15):5797-802. PMC: 3326498. DOI: 10.1073/pnas.1117208109. View

13.

Schirrmacher V, Griesbach A, Ahlert T . Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects. Int J Oncol. 2001; 18(5):945-52. DOI: 10.3892/ijo.18.5.945. View

14.

Gaston D, Odom C, Li L, Markert J, Roth J, Cassady K . Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1. PLoS One. 2013; 8(11):e81768. PMC: 3842420. DOI: 10.1371/journal.pone.0081768. View

15.

Small E, Schellhammer P, Higano C, Redfern C, Nemunaitis J, Valone F . Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006; 24(19):3089-94. DOI: 10.1200/JCO.2005.04.5252. View

16.

Irvine K, Chamberlain R, Shulman E, Surman D, Rosenberg S, Restifo N . Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst. 1997; 89(21):1595-601. DOI: 10.1093/jnci/89.21.1595. View

17.

Adair R, Roulstone V, Scott K, Morgan R, Nuovo G, Fuller M . Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med. 2012; 4(138):138ra77. PMC: 3893925. DOI: 10.1126/scitranslmed.3003578. View

18.

Harrop R, Connolly N, Redchenko I, Valle J, Saunders M, Ryan M . Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res. 2006; 12(11 Pt 1):3416-24. DOI: 10.1158/1078-0432.CCR-05-2732. View

19.

Parato K, Breitbach C, Le Boeuf F, Wang J, Storbeck C, Ilkow C . The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther. 2011; 20(4):749-58. PMC: 3321594. DOI: 10.1038/mt.2011.276. View

20.

Choi K, Kim J, Lee Y, Kim J, Suh B, Kim H . Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Ther. 2006; 13(13):1010-20. DOI: 10.1038/sj.gt.3302759. View